12th Mar 2014 07:00
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
12 March 2014
Shareholder update
Allergy Therapeutics, the fully integrated specialty pharmaceutical company, announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will today release its annual report for the year ended 31 December 2013. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.
Balance Sheet as at 30 September 2013
£ '000
Total Non-Current Assets 14,417
Total Current Assets 17,052Total Current Liabilities (9,863)Total Non-Current Liabilities (6,724)
Total Equity 14,882
Consolidated Income Statement for the 12 months ended 30 September 2013 £ '000Revenue 40,498Profit for the period 890
Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2013.
-Ends-
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Peel Hunt LLP | +44 (0) 20 7418 8900 |
James Steel | |
Clare Terlouw | |
FTI Consulting | +44 (0) 207 831 3113 |
Simon Conway | |
Victoria Foster Mitchell |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
Related Shares:
Allergy Thera.